You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical characteristics of neonates with and without persistent candidemia

From: Persistent candidemia in very low birth weight neonates: risk factors and clinical significance

Variable Persistent candidemia P value Odds ratio (OR) (95% CI)
Yes mean (95% CI) or n (%) No mean (95% CI) or n (%)
Demographics
 Gestational age (wks) 29.6 (27.3, 31.9) 29.7 (28.1, 31.2) 0.766  
 Birth weight (g) 1097.8 (866.4,1309.2) 1229.0 (1051.1,1046.9) 0.029  
 Male gender, n (%) 12 (42.9) 5 (25.0) 0.207 0.44 (0.13–1.57)
 Admission age 1.3 (0.4, 2.2) 1.8 (2.4, 6.0) 0.611  
Risk factors
 Necrotizing enterocolitis 9 (32.1) 1 (5.0) 0.046 9.0 (1.04–78.17)
 Neurodevelopmental impairment 6 (21.4) 6 (30.0) 0.501 0.64 (0.17–2.37)
 Vaginal delivery 13 (46.4) 7 (35.0) 0.430 1.61 (0.49–5.25)
 Fetal membrane rupture (h) 46.4 (25.1, 117.7) 18.8 (37.5, 75.1) 0.143  
 Congentital diseases 15 (53.6) 10 (50.0) 0.867 1.15 (0.37–3.64)
 Abdominal surgery 3 (10.7) 0 (0.0)
 Mechanical ventilation 24 (85.7) 10 (50.0) 0.011 6.00 (1.52–23.70)
 Central venous catheter 15 (59.6) 13 (65.0) 0.430 0.62 (0.19–2.03)
 Intubation 20 (71.4) 3 (15.0) 0.000 14.17 (3.24–61.99)
 Total parenteral nutrition 26 (92.9) 19 (95.0) 0.764 0.68 (0.06–8.11)
 Hospitalization duration (d) 58.8 (33.8, 93.8) 49.3 (32.4, 66.2) 0.147  
 3rdcephalosporins use 16 (59.3) 13 (65.0) 0.689 0.78 (0.24–2.59)
 Carbapenems use 26 (92.9) 16 (80.0) 0.201 3.25 (0.53–19.82)
 Vancomycin use 7 (25.0) 2 (10.0) 0.203 3.00 (0.55–16.31)
 Multiple antibiotic use 18 (64.3) 13 (65.0) 0.959 0.97 (0.29–3.22)
 Antibiotic therapeutic duration (d) 44.5 (24.3, 64.7) 31.1 (16.6, 55.6) 0.015  
 Non-C.albicans 21 (75.0) 8 (40.0) 0.017 4.50 (1.31–15.52)
 Prophylaxis antifungal therapy 25 (89.3) 16 (80.0) 0.375 2.08 (0.41–10.56)
 Antifungal therapeutic duration (d) 11.3 (4.6, 18.0) 9.2 (4.6, 14.4) 0.243  
Outcome
 Death 4 (14.3) 1 (5.0) 0.320 3.17 (10.33–30.73)